Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs VENUS REMEDIES - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS VENUS REMEDIES IPCA LABS/
VENUS REMEDIES
 
P/E (TTM) x 51.7 15.0 344.1% View Chart
P/BV x 5.4 0.9 567.4% View Chart
Dividend Yield % 0.3 0.0 -  

Financials

 IPCA LABS   VENUS REMEDIES
EQUITY SHARE DATA
    IPCA LABS
Mar-23
VENUS REMEDIES
Mar-23
IPCA LABS/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs1,062379 280.2%   
Low Rs768145 529.7%   
Sales per share (Unadj.) Rs243.0415.5 58.5%  
Earnings per share (Unadj.) Rs19.419.9 97.6%  
Cash flow per share (Unadj.) Rs29.744.0 67.5%  
Dividends per share (Unadj.) Rs4.000-  
Avg Dividend yield %0.40-  
Book value per share (Unadj.) Rs230.3344.3 66.9%  
Shares outstanding (eoy) m253.7013.37 1,897.5%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x3.80.6 597.4%   
Avg P/E ratio x47.213.2 358.0%  
P/CF ratio (eoy) x30.85.9 517.9%  
Price / Book Value ratio x4.00.8 522.4%  
Dividend payout %20.60-   
Avg Mkt Cap Rs m232,1203,501 6,629.2%   
No. of employees `000NANA-   
Total wages/salary Rs m12,876570 2,257.2%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m61,6425,555 1,109.6%  
Other income Rs m1,518103 1,470.4%   
Total revenues Rs m63,1605,658 1,116.2%   
Gross profit Rs m9,033602 1,500.4%  
Depreciation Rs m2,616323 809.8%   
Interest Rs m4823 16,391.2%   
Profit before tax Rs m7,453379 1,964.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,534114 2,229.3%   
Profit after tax Rs m4,919266 1,851.7%  
Gross profit margin %14.710.8 135.2%  
Effective tax rate %34.030.0 113.5%   
Net profit margin %8.04.8 166.9%  
BALANCE SHEET DATA
Current assets Rs m51,8933,230 1,606.8%   
Current liabilities Rs m18,058826 2,187.0%   
Net working cap to sales %54.943.3 126.8%  
Current ratio x2.93.9 73.5%  
Inventory Days Days5137 138.7%  
Debtors Days Days6504 1.2%  
Net fixed assets Rs m34,3362,781 1,234.6%   
Share capital Rs m254134 189.8%   
"Free" reserves Rs m58,1674,470 1,301.4%   
Net worth Rs m58,4204,603 1,269.1%   
Long term debt Rs m6,518387 1,685.1%   
Total assets Rs m86,2296,011 1,434.6%  
Interest coverage x16.5130.0 12.7%   
Debt to equity ratio x0.10.1 132.8%  
Sales to assets ratio x0.70.9 77.4%   
Return on assets %6.34.5 140.2%  
Return on equity %8.45.8 145.9%  
Return on capital %12.27.7 159.5%  
Exports to sales %42.90-   
Imports to sales %13.30-   
Exports (fob) Rs m26,434NA-   
Imports (cif) Rs m8,178NA-   
Fx inflow Rs m26,4340-   
Fx outflow Rs m8,1780-   
Net fx Rs m18,2570-   
CASH FLOW
From Operations Rs m8,058366 2,200.0%  
From Investments Rs m-7,250-508 1,426.3%  
From Financial Activity Rs m5,072-6 -89,302.8%  
Net Cashflow Rs m5,881-220 -2,667.6%  

Share Holding

Indian Promoters % 46.3 41.8 110.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 44.8 1.6 2,817.0%  
FIIs % 10.3 1.6 645.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 53.7 58.2 92.2%  
Shareholders   82,809 19,560 423.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   DIVIS LABORATORIES    CIPLA    SUN PHARMA    DR. REDDYS LAB    ZYDUS LIFESCIENCES    


More on IPCA Labs vs VENUS REMEDIES

No comparison is complete without understanding how the stock prices have performed over a period of time.

Here's a brief comparison:

IPCA Labs vs VENUS REMEDIES Share Price Performance

Period IPCA Labs VENUS REMEDIES S&P BSE HEALTHCARE
1-Day 3.35% 7.05% 1.18%
1-Month 4.27% -4.10% -0.75%
1-Year 56.49% 103.11% 61.82%
3-Year CAGR 9.46% 4.62% 18.16%
5-Year CAGR 20.88% 58.05% 19.79%

* Compound Annual Growth Rate

Here are more details on the IPCA Labs share price and the VENUS REMEDIES share price.

Moving on to shareholding structures...

The promoters of IPCA Labs hold a 46.3% stake in the company. In case of VENUS REMEDIES the stake stands at 41.8%.

To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of IPCA Labs and the shareholding pattern of VENUS REMEDIES.

Finally, a word on dividends...

In the most recent financial year, IPCA Labs paid a dividend of Rs 4.0 per share. This amounted to a Dividend Payout ratio of 20.6%.

VENUS REMEDIES paid Rs 0.0, and its dividend payout ratio stood at 0.0%.

You may visit here to review the dividend history of IPCA Labs, and the dividend history of VENUS REMEDIES.

For a sector overview, read our pharmaceuticals sector report.



Today's Market

Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising(Closing)

After opening the day on positive note, Indian share markets gained the momentum as the session progressed and ended on firm footing.